165 related articles for article (PubMed ID: 38167749)
1. Mapping IWQOL-Lite onto EQ-5D-5L and SF-6Dv2 among overweight and obese population in China.
Guo W; Xie S; Wang D; Wu J
Qual Life Res; 2024 Mar; 33(3):817-829. PubMed ID: 38167749
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the measurement properties of the EQ-5D-5L and SF-6Dv2 among overweight and obesity populations in China.
Xie S; Li M; Wang D; Hong T; Guo W; Wu J
Health Qual Life Outcomes; 2023 Oct; 21(1):118. PubMed ID: 37904216
[TBL] [Abstract][Full Text] [Related]
3. Comparative performance and mapping algorithms between EQ-5D-5L and SF-6Dv2 among the Chinese general population.
Xie S; Wu J; Chen G
Eur J Health Econ; 2024 Feb; 25(1):7-19. PubMed ID: 36709458
[TBL] [Abstract][Full Text] [Related]
4. Population Norms for SF-6Dv2 and EQ-5D-5L in China.
Xie S; Wu J; Xie F
Appl Health Econ Health Policy; 2022 Jul; 20(4):573-585. PubMed ID: 35132573
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the measurement properties of SF-6Dv2 and EQ-5D-5L in a Chinese population health survey.
Xie S; Wang D; Wu J; Liu C; Jiang W
Health Qual Life Outcomes; 2022 Jun; 20(1):96. PubMed ID: 35710429
[TBL] [Abstract][Full Text] [Related]
6. Psychometric performance of EQ-5D-5L and SF-6DV2 in measuring health status of populations in Chinese university staff and students.
Zhou HJ; Zhang A; Wei J; Wu J; Luo N; Wang P
BMC Public Health; 2023 Nov; 23(1):2314. PubMed ID: 37993793
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the Measurement Properties of EQ-5D-5L and SF-6Dv2 in COVID-19 Patients in China.
Ding N; Zhou H; Chen C; Chen H; Shi Y
Appl Health Econ Health Policy; 2024 Apr; ():. PubMed ID: 38641755
[TBL] [Abstract][Full Text] [Related]
8. Mapping the cancer-specific QLQ-C30 onto the generic EQ-5D-5L and SF-6D in colorectal cancer patients.
Ameri H; Yousefi M; Yaseri M; Nahvijou A; Arab M; Akbari Sari A
Expert Rev Pharmacoecon Outcomes Res; 2019 Feb; 19(1):89-96. PubMed ID: 30173585
[TBL] [Abstract][Full Text] [Related]
9. Psychometric performance of EQ-5D-5L and SF-6Dv2 in patients with lymphoma in China.
Zhang A; Li J; Mao Z; Wang Z; Wu J; Luo N; Liu P; Wang P
Eur J Health Econ; 2024 Mar; ():. PubMed ID: 38451345
[TBL] [Abstract][Full Text] [Related]
10. Mapping the EORTC QLQ-C30 and QLQ H&N35 to the EQ-5D-5L and SF-6D for papillary thyroid carcinoma.
Huang D; Zeng D; Tang Y; Jiang L; Yang Q
Qual Life Res; 2024 Feb; 33(2):491-505. PubMed ID: 37938402
[TBL] [Abstract][Full Text] [Related]
11. Mapping QLQ-C30 Onto EQ-5D-5L and SF-6D-V2 in Patients With Colorectal and Breast Cancer From a Developing Country.
Yousefi M; Nahvijou A; Sari AA; Ameri H
Value Health Reg Issues; 2021 May; 24():57-66. PubMed ID: 33508752
[TBL] [Abstract][Full Text] [Related]
12. A mapping study in mainland China: predicting EQ-5D-5L utility scores from the psoriasis disability index.
Su J; Liu T; Li S; Zhao Y; Kuang Y
J Med Econ; 2020 Jul; 23(7):737-743. PubMed ID: 32223358
[No Abstract] [Full Text] [Related]
13. Mapping the Chinese Version of the EORTC QLQ-BR53 Onto the EQ-5D-5L and SF-6D Utility Scores.
Liu T; Li S; Wang M; Sun Q; Chen G
Patient; 2020 Oct; 13(5):537-555. PubMed ID: 32382953
[TBL] [Abstract][Full Text] [Related]
14. Mapping study of papillary thyroid carcinoma in China: Predicting EQ-5D-5L utility values from FACT-H&N.
Huang D; Peng J; Chen N; Yang Q; Jiang L
Front Public Health; 2023; 11():1076879. PubMed ID: 36908441
[TBL] [Abstract][Full Text] [Related]
15. EQ-5D-5L and SF-6Dv2 utility scores in people living with chronic low back pain: a survey from Quebec.
Poder TG; Wang L; Carrier N
BMJ Open; 2020 Sep; 10(9):e035722. PubMed ID: 32933957
[TBL] [Abstract][Full Text] [Related]
16. Mapping Dermatology Life Quality Index (DLQI) scores to EQ-5D utility scores using data of patients with atopic dermatitis from the National Health and Wellness Study.
Vilsbøll AW; Kragh N; Hahn-Pedersen J; Jensen CE
Qual Life Res; 2020 Sep; 29(9):2529-2539. PubMed ID: 32297132
[TBL] [Abstract][Full Text] [Related]
17. Measurement properties of the EQ-5D-3L, EQ-5D-5L, and SF-6Dv2 in patients with late-onset Pompe disease.
Xu RH; Luo N; Dong D
Eur J Health Econ; 2024 Mar; ():. PubMed ID: 38472723
[TBL] [Abstract][Full Text] [Related]
18. Testing alternative regression models to predict utilities: mapping the QLQ-C30 onto the EQ-5D-5L and the SF-6D.
Lamu AN; Olsen JA
Qual Life Res; 2018 Nov; 27(11):2823-2839. PubMed ID: 30173314
[TBL] [Abstract][Full Text] [Related]
19. Mapping the Positive and Negative Syndrome Scale scores to EQ-5D-5L and SF-6D utility scores in patients with schizophrenia.
Abdin E; Chong SA; Seow E; Verma S; Tan KB; Subramaniam M
Qual Life Res; 2019 Jan; 28(1):177-186. PubMed ID: 30382480
[TBL] [Abstract][Full Text] [Related]
20. Development of algorithms to estimate the EQ-5D-5L from the FACT-L in patients with lung cancer: a mapping study.
Jiang L; Zhou H; Yang Q; Luo X; Huang D
Qual Life Res; 2024 Mar; 33(3):805-816. PubMed ID: 38148367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
